Letters to the Editor
Early Access
Widespread dermoscopic alterations of multiple melanocytic nevi in a patient receiving vandetanib: implications for dermatological surveillance
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 12 May 2026
96
Views
43
Downloads
Authors
Dear Editor,
Regression-like dermoscopic and histopathological changes in pre-existing melanocytic nevi have increasingly been reported in patients undergoing modern oncologic therapies, particularly immune checkpoint inhibitors (such as ipilimumab, nivolumab, and pembrolizumab) and targeted agents including BRAF and MEK inhibitors. [...]
Downloads
Download data is not yet available.
Citations
1. Belkaid S, Clerc M, Amini-Adle M, et al. Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients. J Eur Acad Dermatol Venereol 2025;39:e600-3.
2. Perier-Muzet M, Boespflug A, Poulalhon N, et al. Dermoscopic evaluation of melanocytic nevi changes with combined mitogen-activated protein kinase pathway inhibitors therapy for melanoma. JAMA Dermatol 2016;152:1162-4.
3. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 2012;148:1183-5.
4. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41.
5. Kong HH, Fine HA, Stern JB, et al. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 2009;145:923-5.
6. Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012;148:1418-20.
7. Bota J, Harvey V, Ferguson C, et al. A rare case of late-onset lichenoid photodermatitis after vandetanib therapy. JAAD Case Rep 2015;1:141-3.
8. Cury-Martins J, Sanches JA. Dermoscopic findings of perifollicular pigmentation associated with vandetanib. Dermatol Pract Concept 2018;8:340-1.
9. Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916-23.
How to Cite
1.
Paolino G, Di Nicola MR, Rizzo N, Mercuri SR. Widespread dermoscopic alterations of multiple melanocytic nevi in a patient receiving vandetanib: implications for dermatological surveillance. Dermatol Reports [Internet]. 2026 May 12 [cited 2026 Jun. 3];. Available from: https://journals.pagepress.net/dr/article/view/10851
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
